Denali Therapeutics (DNLI) Revenue (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly Revenue of $1.3 million for Q3 2023, down 62.46% year-over-year from $3.4 million in Q3 2022, and down 99.57% quarter-over-quarter from $294.1 million in Q2 2023.
Denali Therapeutics (DNLI) Revenue (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Revenue for 6 consecutive years, with $1.3 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Revenue fell 62.46% year-over-year to $1.3 million; the TTM figure through Jun 2024 stood at $1.3 million (down 99.63% YoY), while the FY2023 annual figure was $330.5 million, up 214.6% from the prior year.
- Revenue fell to $1.3 million in Q3 2023 per DNLI's latest filing, from $294.1 million in the prior quarter.
- Across five years, Revenue topped out at $316.8 million in Q4 2020 and bottomed at $52000.0 in Q1 2020.
- Historically, Revenue has averaged $46.0 million across 5 years, with a median of $9.4 million in 2020.
- Annual changes were most pronounced in 2020 — Revenue plunged 98.76% — and 2021, when it soared 15134.62%.
- Denali Therapeutics' Revenue stood at $4.7 million in 2019, then soared by 6681.04% to $316.8 million in 2020, then sank by 84.64% to $48.7 million in 2021, then sank by 79.45% to $10.0 million in 2022, then tumbled by 87.33% to $1.3 million in 2023.
- Business Quant data shows DNLI's Revenue at $1.3 million in Q3 2023, $294.1 million in Q2 2023, and $35.1 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.60 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 294.12 Mn |
| Mar 31, 2023 | 35.14 Mn |
| Dec 31, 2022 | 10.00 Mn |
| Sep 30, 2022 | 3.38 Mn |
| Jun 30, 2022 | 52.48 Mn |
| Mar 31, 2022 | 42.14 Mn |
| Dec 31, 2021 | 48.65 Mn |
| Sep 30, 2021 | 5.29 Mn |
| Jun 30, 2021 | 15.00 Mn |
| Mar 31, 2021 | 7.92 Mn |
| Dec 31, 2020 | 316.81 Mn |
| Sep 30, 2020 | 9.39 Mn |
| Jun 30, 2020 | 5.81 Mn |
| Mar 31, 2020 | 52,000.00 |
| Dec 31, 2019 | 4.67 Mn |
| Sep 30, 2019 | 13.51 Mn |
| Jun 30, 2019 | 4.10 Mn |
| Mar 31, 2019 | 4.21 Mn |